Instructions · QR destination

Product Instructions

Educational reference for storage, handling, biological pathways and safety — the page linked from Regeniq product labels.

  • Before use
  • Storage
  • Pathways
  • Safety
  • References
Important notice

This guide is provided for educational and research-reference purposes only.

The compounds discussed may have different regulatory statuses, approved uses, safety profiles and evidence levels depending on jurisdiction and intended application.

Nothing in this guide should be interpreted as medical advice, a prescription or a recommendation to self-administer any compound.

Use only under the direction of an appropriately qualified healthcare professional or within an appropriately supervised research setting.

Product labels

Scan destinations for Regeniq pens

Each pen links to its product page. Use the chapters above for storage, pathways and safety education.

View products
01 — Introduction

Understanding peptide research

Peptides are short chains of amino acids. In biological systems they often act as messengers, helping cells communicate and coordinating processes such as signalling, regulation and repair.

Researchers study peptides because specific sequences can interact with specific receptors or pathways. That specificity makes them useful tools for probing biology — and, in some cases, for developing medicines.

It is essential to distinguish research interest from clinical application. Laboratory findings, animal data and early human studies do not automatically establish safety or efficacy for human use.

Evidence quality and regulatory status vary by compound, indication and jurisdiction. Claims in this guide are intentionally measured and should be read alongside primary literature and official product documentation.

Scientific visualisation of molecular signalling between peptide structures and cellular receptors
02 — Preparation

Before use

Before handling or evaluating any compound in a research or clinical context, confirm identity, documentation and suitability.

Verify product identity
Verify concentration and presentation
Review product documentation
Confirm storage requirements
Review regulatory status in your jurisdiction
Review contraindications
Review potential interactions
Consult an appropriately qualified professional
Never assume protocols for one compound apply to another
Temperature-controlled laboratory storage environment for research materials
03 — Handling

Storage & handling

Integrity depends on temperature, light exposure, packaging condition, expiration dating, contamination control and transport conditions. Child-safe storage is also essential in any environment where materials are held.

Storage requirements vary by compound and formulation. Always follow the applicable product documentation.

Temperature — maintain the range stated for the product
Light exposure — protect light-sensitive materials as directed
Packaging integrity — inspect seals and containers before use
Expiration — do not use beyond labelled dating
Contamination — use aseptic technique where required
Transport — protect against temperature excursion and damage
01
Category

Metabolic & incretin peptides

This category includes incretin-pathway and related metabolic signalling compounds studied in relation to glycaemic regulation, appetite signalling and body-composition research. Regulatory status differs substantially between compounds and markets.

Retatrutide
Investigational · Triple agonist research

Pathway

Described in research as an agonist of GLP-1, GIP and glucagon receptors.

Research areas

Metabolic signalling, body-composition and glycaemic research contexts.

Evidence status

Investigational. Clinical development status should be verified against current trial registries and regulatory notices.

Limitations

Not presented here as an approved medicine. Local regulatory status must be confirmed before any clinical application.

Tirzepatide
Approved medicine in some jurisdictions · Dual agonist

Pathway

Dual agonist activity at GIP and GLP-1 receptors, as described in authorised product information where approved.

Research / clinical areas

Type 2 diabetes and weight-management indications where specifically authorised.

Evidence status

Approved for defined indications in certain markets; labelling governs use.

Limitations

Approval, indication and risk profile vary by jurisdiction. Do not extrapolate beyond labelled use.

Semaglutide
Approved medicine in some jurisdictions · GLP-1 receptor agonist

Pathway

GLP-1 receptor agonist activity, as described in authorised prescribing information where approved.

Research / clinical areas

Glycaemic control and weight-management indications where specifically authorised.

Evidence status

Established medicinal product in authorised markets for labelled indications.

Limitations

Formulation, dose and indication are product-specific. Follow authorised documentation only.

Cagrilintide
Investigational · Amylin analogue research

Pathway

Amylin-analogue signalling studied in metabolic and appetite-regulation research.

Research areas

Metabolic combination research, including studies exploring use alongside incretin-pathway agents.

Evidence status

Investigational. Confirm current development and regulatory status before any application.

Limitations

Not presented here as an approved standalone medicine.

Scientific visualisation of metabolic peptide hormone signalling pathways
02
Category

Recovery & growth-factor peptides

Compounds in this group are studied in relation to growth-hormone releasing pathways, IGF-1 signalling, recovery research, tissue signalling and body-composition science. Many remain research-oriented outside authorised medical products.

Microscopic-style visualisation of growth-factor and cellular signalling pathways
CJC-1295
Research reference · GHRH analogue family

Pathway

Studied as a growth hormone–releasing hormone (GHRH) analogue affecting GH axis signalling.

Research areas

GH secretion dynamics, recovery and body-composition research contexts.

Evidence status

Primarily research/investigational outside authorised medicinal frameworks.

Limitations

Variants and formulations differ. Do not generalise findings across presentations.

Ipamorelin
Research reference · Ghrelin-mimetic / GHS pathway

Pathway

Growth hormone secretagogue pathway research related to ghrelin-receptor signalling.

Research areas

GH release patterns and recovery-oriented research discussions.

Evidence status

Research reference; not presented as an approved therapy here.

Limitations

Human clinical evidence and regulatory status must be assessed independently.

Tesamorelin
Approved medicine in some jurisdictions · GHRH analogue

Pathway

GHRH analogue activity as described in authorised labelling where approved.

Research / clinical areas

Authorised indications relating to reduction of excess abdominal fat in specific HIV-associated contexts where labelled.

Evidence status

Approved for defined indications in certain markets.

Limitations

Use is indication- and jurisdiction-specific. Off-label extrapolation is outside this guide.

IGF-1 LR3
Research reference · IGF-1 pathway

Pathway

Long-acting IGF-1 analogue researched in relation to insulin-like growth factor signalling.

Research areas

Tissue signalling, recovery and body-composition research literature.

Evidence status

Research-oriented; not presented as an approved general medicine here.

Limitations

Potency and safety considerations require specialist oversight. Not for self-administration.

03
Category

Immunity & longevity

Selected peptides are studied for immune modulation and ageing-biology research. Evidence ranges from preclinical models to limited human data. Longevity-related claims require particular caution.

Epithalon
Research reference · Ageing-biology research

Pathway

Studied in ageing-biology and pineal-related research contexts; mechanistic claims remain under investigation.

Research areas

Cellular ageing research and longevity-oriented scientific discussion.

Evidence status

Primarily research/experimental literature; not established as a general anti-ageing medicine.

Limitations

Do not interpret research interest as proven clinical benefit.

Thymosin Alpha-1
Research / authorised in limited settings · Immune signalling

Pathway

Thymic peptide researched for immune-regulatory signalling.

Research areas

Immune function research; regulatory status varies widely by country.

Evidence status

Authorised or restricted depending on jurisdiction; confirm local status.

Limitations

Not a substitute for standard-of-care immunotherapy or vaccination guidance.

Scientific visualisation related to immune cells and cellular longevity research
04
Category

Cognitive peptides

Compounds discussed here appear in neuroregulatory, cognitive, stress-related, sleep and neuroendocrine research. Experimental findings must not be presented as established medical outcomes.

Elegant scientific visualisation of neural networks and molecular signalling
Semax
Research reference · ACTH-fragment related

Pathway

ACTH-related peptide fragment studied in neuroregulatory research.

Research areas

Cognitive and neuroprotective research discussions in selected literature.

Evidence status

Research reference; regulatory recognition differs by region.

Limitations

Does not establish clinical cognitive enhancement claims.

Selank
Research reference · Tuftsin-related analogue

Pathway

Tuftsin-related analogue studied in stress- and anxiety-related signalling research.

Research areas

Stress-related pathways and neuroregulatory research contexts.

Evidence status

Research reference with regionally variable status.

Limitations

Not a substitute for evidence-based mental health care.

DSIP
Research reference · Sleep-related peptide research

Pathway

Delta sleep-inducing peptide studied historically in sleep and neuroendocrine research.

Research areas

Sleep architecture and stress-axis research literature.

Evidence status

Historical and experimental research interest; not established standard sleep therapy.

Limitations

Findings are not clinical treatment recommendations.

05
Research context · Limitations apply

Melanocortin peptides

Melanocortin-pathway peptides relate to alpha-MSH biology and melanin-related research. Status and safety considerations require careful reading of evidence and regulation.

Melanotan II
Research reference · Melanocortin receptor agonist

Pathway

Non-selective melanocortin receptor agonist related to alpha-MSH signalling and melanin biology research.

Research areas

Pigmentation biology and melanocortin-system research.

Evidence status

Research/experimental context; not an authorised tanning medicine in major regulated markets.

Limitations

Associated with safety concerns in unsupervised use. This guide does not endorse self-administration or cosmetic tanning use.

Molecular visualisation of melanocortin receptor signalling research
06
Highly experimental

Experimental research compounds

Materials in this section are discussed only in a preclinical or early experimental research context. They are not described as treatments, cures or therapies.

Preclinical molecular research visualisation of a peptide interacting with cellular membrane structures
PNC-27
Highly experimental · Preclinical research

Pathway

Peptide studied in laboratory models for interactions involving membrane-associated proteins in cancer-biology research.

Research areas

Preclinical oncology research literature and membrane biology.

Evidence status

Highly experimental. Preclinical findings do not establish human safety or efficacy.

Limitations

Not a cancer treatment. Do not interpret laboratory observations as clinical recommendations.

07
Category

Hormonal compounds

Some related hormonal agents appear alongside peptide research discussions. Established medicines must be clearly distinguished from experimental or non-medical contexts. No dosing protocols are provided.

Testosterone cypionate
Established medicine in labelled contexts · Androgen

Pathway

Androgen receptor signalling; endogenous testosterone biology.

Clinical context

Authorised for specific hypogonadism and related indications where labelled.

Evidence status

Established medicinal product under regulated prescribing frameworks.

Limitations

Prescription-only in most jurisdictions. Non-medical use carries significant risk.

HCG
Established medicine in labelled contexts · Gonadotropin

Pathway

Luteinising-hormone receptor signalling via human chorionic gonadotropin.

Clinical context

Authorised uses include selected fertility and endocrine indications where labelled.

Evidence status

Established medicinal product for defined labelled uses.

Limitations

Indication-specific. Not discussed here for unsupervised or non-labelled use.

Endocrinology research visualisation of hormone molecules and receptor signalling
Administration

Dosing & administration

Dosage and administration requirements are specific to the compound, formulation, concentration, route, indication and individual context.

This reference intentionally does not provide individualized dosing instructions.

Always follow authorized product documentation and qualified professional guidance.

11 — Safety

Safety first

Before any supervised research or clinical consideration, review personal and product-specific risk factors with a qualified professional.

History

Medical history and current conditions

Medications

Current medicines and supplements

Allergies

Known sensitivities and reactions

Labs

Relevant laboratory information

Interactions

Potential drug and pathway interactions

Status

Pregnancy, breastfeeding and regulatory context where applicable

Route

Administration route and technique under supervision

Concentration

Product strength and presentation

Regulation

Local legal and labelling status

Seek immediate medical attention for severe or unexpected reactions.
Clean professional clinical laboratory safety environment
References

Where to verify information

This page does not invent compound-specific citations. Use authoritative databases and regulators to verify current evidence and labelling.

Database

PubMed

Peer-reviewed biomedical literature index for primary research and reviews.

Open PubMed
Registry

ClinicalTrials.gov

Public registry of clinical studies, useful for checking development status.

Open ClinicalTrials.gov
Regulator

FDA Drugs / Labels

Official US labelling and approval information for authorised medicines.

Open Drugs@FDA
Regulator

EMA Medicines

European public assessment information for authorised medicines.

Open EMA Medicines
Closing statement

Research-only disclaimer

Information describing experimental compounds, mechanisms, research findings or historical research protocols is provided solely to facilitate scientific and educational discussion.

Research information does not establish safety or efficacy in humans and should not be interpreted as a recommendation for treatment, prevention, diagnosis or self-administration.

Always consult applicable regulatory information, product documentation, published evidence and an appropriately qualified healthcare professional before clinical or research application.

Need clinician-led guidance?

Book a private online consultation for product questions, clinic partnerships or regenerative wellness education.